+ women with metastatic breast cancer received up to 14 vaccinations with MDA-MB-231-CD80, an HLA-A2 + allogeneic breast cancer cell line, which had been lipofected with the cDNA for the CD80 costimulatory molecule. Tumor cells were administered with BCG or GM-CSF as an adjuvant. Sera obtained before and after vaccination were analyzed for antibodies to tumor cell lysate, MUC1, HER2/neu and p53. Since the cell line was grown in fetal bovine serum (FBS), sera were also analyzed for antibodies to FBS. Eighteen of 24 patients for whom sera were available exhibited anti-FBS activity at baseline. Eleven of these 18 patients and all six patients without baseline anti-FBS activity showed an increased titer after vaccination. The anti-FBS activity required that serum samples be absorbed in excess FBS to detect specific antibodies to tumor cell lysate. A two-fold increase in the titer of IgG specific to tumor cell lysate was observed in 6 patients. Eight of 24 patients made an antibody response to HER-2/neu, four of 24 to MUC1 and one of 24 to p53. Although antibody production to a variety of tumor cell-associated antigens was detected our results suggest that a whole cell vaccine comprising a CD80-transfected allogeneic breast cancer cell line with adjuvant BCG or GM-CSF was not a reliable method to induce significant antibody responses in women with advanced breast cancer. Key Words: Antibodies-BS-ER-2/neu-MB-231-UC1.
The potential value of a vaccine that induces the production of high titer antibodies to tumor-associated antigens is illustrated by the successful treatment of patients with breast cancer and non-Hodgkins lymphoma (NHL) with exogenously administered monoclonal antibodies. Women with metastatic breast cancer that overexpresses Her2/neu experience increased survival after treatment with trastuzumab (Herceptin; Genentech Inc., South San Francisco, CA, U.S.A.), a humanized monoclonal antibody with high affinity for HER-2/neu (1,2), when given with chemotherapy (3) . The FDA has also approved anti-CD20, rituximab, for the treatment of patients with CD20 + NHL (4) . Furthermore, women with breast cancer who develop a natural immune response to MUC1 (5) and CEA (6) survive longer than women who fail to develop an antibody response. Production of tu-mor-specific antibodies after vaccination also correlates with improved survival in patients with melanoma (7) (8) (9) (10) (11) .
In an attempt to induce immune responses to tumor antigens in women with metastatic breast cancer, we conducted a phase I trial using a genetically modified whole cell vaccine. The breast cancer cell line, MDA-MB-231, was modified by lipofection with the cDNA for the costimulatory molecule CD80, the expression of which improves direct presentation of antigens by tumor cells to host T cells and also enhances cross-priming (12) . CD80 gene modification enabled tumor cells to provide signal one, binding of the T-cell receptor to the appropriate tumor-associated peptide/MHC complex, and signal two, generated by the interaction of CD80 and its ligand, CD28, on the responding T cell. Murine tumors that normally grow progressively can be rejected by their hosts, if the tumor cells are induced to express CD80 by genetic modification (13) (14) (15) . Human tumor cells that express CD80 after genetic modification activate healthy donor and patient T lymphocytes in vitro better than unmodified, CD80-negative parental tumor cells (16) . Importantly, once CD80-transfected tumor cells have activated tumor-specific T cells, the effector T cells can kill CD80-modified and unmodified parental tumor cells. This report describes the antibody response of women with refractory metastatic breast cancer after serial vaccination with the CD80 gene-modified allogeneic breast cancer cell line, MDA-MB-231.
PATIENTS AND METHODS

Patients
From 1997 to 2001, 30 HLA-A2-positive women with metastatic breast cancer were enrolled in a phase I whole cell vaccine trial at Providence Portland Medical Center (PPMC), Portland, OR. All patients had stage IV breast cancer, had failed previous treatment, and did not receive hormonal therapy or chemotherapy during vaccination. The age of patients ranged from 31 to 70 years (mean 53 years). Written informed consent was obtained from all patients according to the policies of the Institutional Review Board of PPMC. The Institutional Biosafety Committee approved the protocol.
Vaccine Preparation and Administration
MDA-MB-231 (MB-231 hereafter) was obtained from the American Type Culture Collection (ATCC, Rockville, MD, U.S.A.). It was established in 1974 from the pleural effusion of a 51-year-old woman (17) . It is HLA-
A2
+ , expresses HER2/neu, MUC1, and has a mutation in p53 (Khleif, personal communication, July 6, 2001 ). The safety of vaccination with MB-231 has been established (18) . MB-231 was modified to express CD80 (B7.1) by lipofection with the CMV-B7 vector, which was provided by Dr. Robert Fenton (University of Maryland, Greenebaum Cancer Center, Baltimore, MD, U.S.A.) (19) . The Recombinant DNA Advisory Committee (Bethesda, MD, U.S.A.) has approved this plasmid. A Master Cell Bank was created and the gene-modified tumor cells were tested for adventitious virus. By flow cytometric analysis modified and unmodified tumor cells exhibited similar frequencies of HER2/neu (> 95%) and p53 (23%) positive cells, the frequency of MUC1 positive cells was higher in the modified cells (19%) than in the original cell line (10%) (data not shown).
The tumor cells were suspended in 90% FBS (Gibco BRL, Grand Island, NY, U.S.A.) and 10% dimethylsulfoxide (Sigma, St. Louis, MO, U.S.A.) and stored in liquid nitrogen. Before vaccination cells were thawed and grown in complete media, which included: RPMI-1640 supplemented with 1% NEAA, 1% sodium pyruvate, 1% L-glutamine, and 0.1% gentamicin (all BioWhittaker, Walkersville, MA, U.S.A.) and 10% FBS for 1-2 weeks. On the day of vaccination, cells were harvested after trypsinization (Trypsin-EDTA, Gibco BRL), lethally irradiated (10,000 cGy), washed, and injected subcutaneously. Depending on the cohort, each patient received 10 7 or 10 8 cells with adjuvant GM-CSF (Immunex, Seattle, WA, U.S.A.) or 2 × 10 7 CFU BCG (Litton Bionetics, Rockville, MD, U.S.A.) ( Table 1) . Three vaccinations were given every 2 weeks followed by additional vaccinations every month for 3 months. Additional monthly vaccinations were permitted if patients exhibited tumor regression or stable disease. Peripheral blood cells, serum, and plasma were obtained by venipuncture and/or leukapheresis before treatment and at the completion of the series of vaccinations. Serum samples obtained before and after vaccination were available from 24 patients.
Detection of Antibodies by ELISA
MB-231-CD80 Tumor Cell Lysate
MB-231-CD80 and Femx, a melanoma cell line (NIH, NCI) used as a negative control, were lysed by adding 0. The serum samples were then titrated 100 L/well (1:100 to 1:12,800). After overnight incubation at 4°C, the plates were washed four times with washing buffer and peroxidase-conjugated affinity-purified donkey antihuman IgG (H+L) (Jackson ImmunoResearch, West Grove, PA, U.S.A.) diluted 1:10,000 was added for 45 minutes. Plates were washed seven times and developed for 4 minutes with 100 L peroxidase substrate per well (tetramethylbenzidine [TMB]; Microwell, Kirkegaard & Perry Laboratories, Gaithersburg, MD, U.S.A.). Coloration was stopped by adding 100 L 83% H 3 PO 4 , per well. The reaction product was quantified at 450 nm in an ELISA microplate reader (Model: EL312e; Bio-Tek Instruments, Frederick, MD, U.S.A.). During our initial screening, we identified patients and healthy subjects whose sera contained low and high levels of antibodies to MB-231 and FBS. These samples were used to standardize the assay; samples with low antibody levels were used as negative controls, and those with high levels as positive controls. Samples obtained before and after vaccination were analyzed in the same plate. In experiments that did not include both pre-and postvaccination samples, the assays were standardized by allowing the same developing time for each plate. A positive response was defined as a two-fold increase in IgG titer in postvaccination samples compared with prevaccination samples that was consistent through several dilutions.
The assays were performed in duplicate for each sample and the results are presented as the mean of the readings in optical density units (OD).
FBS
To measure antibodies to FBS, plates were coated with 50% FBS in coating buffer and analyzed as described above.
HCMV
Plates were coated with human cytomegalovirus (HCMV) viral lysate (ABI, Columbia, MD, U.S.A.), 1:2,000 and 1:4,000 (final concentrations 0.5 g/mL and 0.25 g/mL) at 4°C overnight. Specific IgG to HCMV (Virotrol ToRCH-M, Blackhawk Biosystems, Inc., San Ramon, CA, U.S.A.) was diluted 1:100 in HBSS alone or in HBSS containing 10, 25, or 50% FBS and incubated for 45 minutes in polypropylene tubes. Samples (100 L) were titrated into the 96-well flat-bottom plate, coated with HCMV for an overnight incubation at 4°C. The ELISA was performed as described above.
MUC1
The samples were tested for reactivity against a bovine serum albumin (BSA)-conjugated 60-mer MUC1 as described previously (20) .
HER2/neu and p53
A previously described ELISA was used to detect IgG specific for HER2/neu (21, 22) and a similar assay employing TIB116, a murine monoclonal antibody directed against human p53, was performed to detect IgG to p53. 
Statistical Analysis
Data were analyzed with simple descriptive and graphical techniques. Comparisons of numbers of responders to FBS and MB-231-CD80 lysate between cohorts were performed using Fisher exact tests. All probability values are two-tailed. A P value < 0.05 was considered significant.
RESULTS
Antibody Response to Tumor Cell Lysate
To measure antibodies to MB-231-CD80, we developed an ELISA based on tumor cell lysate. Sera from the first few patients tested exhibited such high binding to tumor cell lysate that we suspected the presence of antibodies to FBS. Previous studies have shown that patients vaccinated with cells grown in media containing FBS develop antibodies to FBS (23) (24) (25) . To address this issue, an ELISA was performed with FBS-coated microtiter plates. Overall, 18 of 24 patients had pre-existing antibodies to FBS. Eleven of these patients exhibited at least a two-fold increase in the titer after vaccination. All six patients without FBS activity at baseline developed antibodies after vaccination. Thus, 17 patients exhibited at least a 2-fold increase in their titer of anti-FBS antibodies after vaccination. The results from two representative patients are shown in Figure 1 . In patient bc24, high titers of antibodies were present before and after vaccination, while in patient bc114 only sera obtained after vaccination had anti-FBS activity. There were no significant differences in anti-FBS production between cohorts (Table 1) .
To facilitate the detection of tumor-specific antibodies each serum sample was absorbed with FBS before the ELISA. Postvaccination serum samples from eight patients that exhibited anti-FBS IgG were preabsorbed by dilution in 10%, 25% or 50% FBS followed by an ELISA assay against FBS proteins ( Fig. 2A) . Incubation of sera in Ն 10% FBS for 45 min was required to reduce binding to background levels. Therefore, to detect breast cancerspecific antibodies all serum samples were preabsorbed with 25% FBS. To ensure that FBS preabsorption did not non-specifically inhibit immunoglobulin from binding to its specific antigen, we showed that FBS preabsorption did not affect the detection of antibodies to HCMV. Known concentrations of IgG HCMV antibodies were incubated in 0, 10, 25 and 50% FBS before titration into HCMV-coated plates. HCMV antibodies were still detectable with only a slight reduction in the OD readings in serum samples preabsorbed with up to 50% FBS (Fig.  2B) .
Since FBS preabsorption did not inhibit the detection of specific antibodies to CMV, the same method was used to detect breast cancer-specific antibodies. Pre-and postvaccination serum samples from 24 patients were assayed for IgG against the tumor cell lysate after preabsorption in HBSS containing 25% FBS. A positive response was defined as a two-fold increase in IgG titer that was maintained through at least two dilutions in FBS-absorbed postvaccination compared with prevacci-
FIG. 1.
IgG antibodies to FBS were present in breast cancer patients before vaccination and increased after vaccination. Plates were coated with FBS, patients' sera were diluted and added to the plate, and an ELISA was performed. Prevaccination samples were taken 2 weeks before the first vaccination. Postvaccination samples were taken after (A) two vaccinations (bc24) and (B) three vaccinations (bc114).
--ᮀ--‫ס‬ Prevaccination; --‫ס‬ Postvaccination. nation samples. An increase in antibody to tumor cell lysate was observed in six of 24 patients after vaccination (Tables 1 and 2 ). An example of the ELISA data from a responding (bc114) and a nonresponding patient (bc24) is depicted in Figure 3 . Serum from patient bc114 exhibited significantly more binding to the tumor cell lysate after vaccination (filled squares) compared with before vaccination (open squares). After preabsorption with FBS, there was a marked decline in OD for both specimens; however, there was still significantly more binding activity in serum obtained after vaccination To determine whether the dose of tumor cells or the adjuvant affected the immune response, antibody production to tumor cell lysate by patients from the six different cohorts was compared. Since five patients were treated in each cohort and paired serum samples were not available for all patients any observed differences could have occurred by chance alone. There was a significant difference in response rate favoring cohort 4 when compared with cohort 1 (P ‫ס‬ 0.0476, by Fisher's exact probability test), suggesting that the dose of tumor cells might be important. No antibody production to tumor cell lysate was observed at a GM-CSF dose of 250 mcg/m 2 /d. A possible effect of GM-CSF is further supported by the significant difference in response rate between the two doses of GM-CSF at the highest vaccine cell dose (10 8 ) in favor of the lower dose of GM-CSF, cohort 4 versus 5 (P ‫ס‬ 0.0476). These observations must be considered with caution because of the small number of samples and because corrections for multiple comparisons were not made.
Antibody Responses to MUC1, Her2/neu, and p53
Patients' sera were also tested for antibodies to MUC1, HER-2/neu, and p53. Among the 24 patients tested, four patients (bc48, bc78, bc106, and bc148) showed a slight increase in IgG antibody titer and one patient (bc61) showed a slight increase in IgM titer to MUC1 after vaccination. Patient bc109 exhibited a high level of MUC1 IgM in the pretreatment sample, as did bc24 for MUC1 IgG antibody. Mean MUC1 IgG and IgM levels were not significantly different in the pre-and postvaccination samples (Fig. 4A) . Eight of 24 patients (bc16, bc34, bc53, bc78, bc102, bc106, bc134, and bc142) showed a slight increase in IgG antibody titer to HER-2/neu after vaccination and in four patients there was a slight decrease in IgG titer. Mean HER-2/neu antibody levels were not different in the pre-and postvac- 
TABLE 2. Correlation of response and median vaccination
cination samples (Fig. 4B) . For most patients, p53 antibodies were undetectable in both pre-and postvaccination samples. In one patient, bc148, there was a low, but significant increase in p53 antibody titer. Three of the seven patients that responded to tumor cell lysate showed an increased titer to MUC1 (bc76, bc106, and bc148), one also showed an increased titer to MUC1 and HER-2/neu (bc106) and one exhibited an increased antibody titer to MUC1 and p53 (bc148).
DISCUSSION
This study describes antibody production by women with metastatic breast cancer after vaccination with a CD80 gene-modified, HLA-A2 + allogeneic breast cancer cell line. Pre-and postvaccination serum samples were available from 24 of the 30 patients enrolled. Serum samples analyzed by ELISA showed a two-fold increase of IgG titer to tumor cell lysate, which was the criteria for calling a response positive, in six patients. Three of the four patients in cohort 4 developed antibodies and in no other cohort was there more than two responders. Based on the higher fraction of responders in cohort 4, the optimal dose to induce tumor cell specific antibodies would be 10 8 MB-231-CD80 cells combined with 100 mcg/m 2 /d GM-CSF. There was no obvious clinical benefit to antibody responses since none of the patients experienced tumor regression. We conclude that each cohort was too small to detect anything except a very major difference in the level of antibody production. Our observation that the magnitude of the response to FBS (data not shown) and the number of patients responding to tumor cell lysate and tumor-associated antigens increased with the total number of vaccinations indicates that multiple vaccinations induce a stronger response (Table 2) . However, healthier patients or patients with a smaller tumor burden or slower growing tumors may simply receive more vaccinations because they remain on the trial longer. These patients may have the better immune system, allowing them to produce more antibody irrespective of the number of vaccinations they receive.
Tumor cell lysate may not be the optimal target to detect breast cancer-specific antibodies because it may contain a low concentration of specific tumor antigens. This may, in turn, limit the sensitivity of the ELISA and explain the small number of patients with detectable antibodies to the lysate. Using an increased concentration of tumor cell lysate to coat the plates did not increase the detection of antibodies (data not shown). We found that eight of 24 patients made an antibody response to HER-2/neu, one of 24 to p53 and four of 24 to MUC1 after vaccination with MB-231. The higher level of HER2/neu expression compared with MUC1 and p53 expression might explain the higher number of responders to HER2/neu. There was no correlation between antibody titers to HER2/neu before or after vaccination and the level of expression of the HER2/neu protein by the patient's tumor (data not shown). The low incidence of HER2/neu-specific immunity in our patients is in accord with a previous study, where only 3 of 45 patients with advanced stage HER2/neu-overexpressing breast and ovarian cancers had HER2/neu-specific IgG antibodies (21) . Anergy associated with malignancy is not likely to be the explanation since all patients in the study by Disis et al. (21) responded to tetanus toxoid and the majority of our patients made antibodies to FBS.
The detection of breast cancer-specific antibodies was complicated by the presence of antibodies to FBS. Because of the number of cells required for vaccination, or a desire to genetically engineer tumor cells to augment their immunogenicity, most cell-based vaccines require ex vivo cell culture. Media used for the in vitro expansion of these cells is commonly supplemented with FBS (26) . Because of its allergenic and antigenic properties (27) (28) (29) , and rare episodes of anaphylactic reactions (30, 31) , many investigators have attempted to culture cells in serum-free media or media supplemented with autologous serum. The MB-231 cells used in this study could not be grown in serum free media. Since many assays use FBS or one of its components as a blocking reagent, it is important to recognize that the antibodies to FBS could interfere with the determination of the tumorspecific response.
Anti-FBS antibodies were present in almost all healthy individuals, in 18 of 24 patients before vaccination and were enhanced after vaccination with the MB-231cell line. There are other reports of increased antibody titer to components of FBS after treatment with cell preparations (23) (24) (25) . Another report showed a decreased response to the target cells after absorption of serum samples in a plate coated with FBS (32) . Some studies fail to account for the possible interference of antibodies to components of FBS when assaying antibodies to tumor derivatives (11, 24, 32) . Our results suggest that if a cell line used to prepare a vaccine is cultured in FBS, one needs to exclude the presence of an antibody response to components of FBS before concluding that induction of tumorspecific antibodies has occurred. In some cases preabsorption of sera with FBS failed to eliminate binding to the lysate-coated plate in prevaccination sera. We attribute this to the possibility of antimucin antibodies that have been found in the sera of healthy women and breast cancer patients (20) , or possibly antibodies to other breast cancer antigens. In conclusion, we found that a whole cell vaccine employing MB-231 transfected with CD80 was unable to induce high-titered antibody responses to breast cancer-associated antigens in a majority of patients.
